Monizzi Giovanni, Olivares Paolo, Makmur Giulio, Fabbiocchi Franco, Grancini Luca, Mastrangelo Angelo, Ferrari Cristina, Galli Stefano, Montorsi Piero, Bartorelli Antonio L
Centro Cardiologico Monzino, IRCCS, Milan, Italy.
Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.
Front Cardiovasc Med. 2022 Nov 2;9:922696. doi: 10.3389/fcvm.2022.922696. eCollection 2022.
Conduction disorders (CD) are the most common complications after Transcatheter Aortic Valve Implantation (TAVI). The last generation of Edwards balloon expandable valves, the SAPIEN 3 Ultra (S3U), is provided with an external sealing skirt that aims to further reduce paravalvular leakage (PVL) compared to SAPIEN 3 (S3) and could potentially lead to higher CD rate. We sought to investigate the rate of new-onset CD in patients undergoing TAVI with the S3 or S3U valve.
We included 582 consecutive patients undergoing TAVI in a single high-volume Center. Patients with previously implanted pacemaker and Valve in valve procedures were excluded. CD rate was evaluated early after implantation and at discharge.
No significant difference in the overall CD rate was found between S3 and S3U patients both immediately after the procedure (S3 45.5% vs. S3U 41.8%, = 0.575) and at discharge (S3 30.4% vs. S3U 35.6%, = 0.348) with low rate of permanent pacemaker implantation (S3 6.3% vs. S3U 5.5%, = 0.749). No significant differences were found also in patients with pre-existing atrial fibrillation (S3 8.2% vs. S3U 5%, = 0.648). A significantly lower rate of PVL was found with S3U compared to S3 (S3 42% vs. S3U 26%, = 0.007). According to the manufacturer's guidelines we confirmed that S3U were implanted in a significantly higher position compared to S3 (S3 4.89 ± 1.57 mm vs. S3U 4.47 ± 1.36 mm, = 0.001).
No significant difference in the rate of CD, including the need for PPM implantation, was found in patients undergoing TAVI with the S3 compared to S3U. Moreover, S3U significantly reduced the PVL rate.
传导障碍(CD)是经导管主动脉瓣植入术(TAVI)后最常见的并发症。最新一代的爱德华兹球囊扩张瓣膜,即SAPIEN 3 Ultra(S3U),配备了外部密封裙边,旨在与SAPIEN 3(S3)相比进一步减少瓣周漏(PVL),但可能会导致更高的CD发生率。我们试图研究接受S3或S3U瓣膜TAVI治疗的患者新发CD的发生率。
我们纳入了一家高容量单一中心连续接受TAVI治疗的582例患者。排除先前植入起搏器和瓣膜中瓣膜手术的患者。在植入后早期和出院时评估CD发生率。
在术后即刻(S3为45.5% vs. S3U为41.8%,P = 0.575)和出院时(S3为30.4% vs. S3U为35.6%,P = 0.348),S3和S3U患者的总体CD发生率无显著差异,永久起搏器植入率较低(S3为6.3% vs. S3U为5.5%,P = 0.749)。在已有心房颤动的患者中也未发现显著差异(S3为8.2% vs. S3U为5%,P = 0.648)。与S3相比,S3U的PVL发生率显著更低(S3为42% vs. S3U为26%,P = 0.007)。根据制造商的指南,我们证实S3U的植入位置比S3显著更高(S3为4.89±1.57 mm vs. S3U为4.47±1.36 mm,P = 0.001)。
与S3U相比,接受S3瓣膜TAVI治疗的患者在CD发生率(包括PPM植入需求)方面无显著差异。此外,S3U显著降低了PVL发生率。